Streptozocin
Streptozocin is a chemotherapy drug that seeks out pancreatic islet cells, approved in 1982 for the rare tumours that arise from them; the same selectivity makes it the standard way to induce diabetes in laboratory animals.
Overview
Streptozocin, an antibiotic from Streptomyces achromogenes, carries a glucose group that lets islet cells take it up through GLUT2. The FDA approved it in 1982 for metastatic islet cell carcinoma of the pancreas, where it produced responses alone and with fluorouracil or doxorubicin in the Eastern Cooperative Oncology Group trials of the 1980s. Kidney toxicity is dose-limiting and nausea is severe. Streptozocin-based chemotherapy remains a guideline option for progressive pancreatic neuroendocrine tumours, though capecitabine with temozolomide and the targeted drugs everolimus and sunitinib are used more often, and it is the standard tool for creating diabetic animal models.
A glucose-linked nitrosourea taken up by the GLUT2 transporter, which is why it homes to pancreatic islet cells; it methylates DNA and depletes NAD, killing the cells.
1.Streptozocin slips into a pocket on its target.
- AmivantamabApproved
- CamizestrantApproved
- Comprehensive genomic profilingStandard of care
- Liquid biopsy (ctDNA)Standard of care
- LorlatinibApproved
- MRD / molecular residual disease testingEstablished
- ADC payload neutralisersPhase 1
- BGB-16673Phase 3
- Bispecific ADCPhase 3
- BRUIN CLL-321Positive
- CaDAnCe-304Recruiting
- CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)Active
- A clone report from blood at every treatment cycle
- A fast route to the matched drug when it is licensed for another cancer
- A multi-cancer platform trial of adaptive (dose-holiday) therapy
- A national rapid research autopsy network for end-stage cancer
- A standard evolvability score for every tumour
- A standing platform trial that assigns treatment by how the tumour escaped
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance atlas · Lines of therapy.
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 1982 | Metastatic islet cell carcinoma of the pancreas |
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Streptozocin" OR ABSTRACT:"Streptozocin" OR TITLE:"Zanosar" OR ABSTRACT:"Zanosar" OR TITLE:"Streptozotocin" OR ABSTRACT:"Streptozotocin") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Streptozocin, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentFloxuridine
Shares Fluorouracil (5-FU), Cytotoxic chemotherapy and the tag chembl-universe.
- TreatmentRaltitrexed
Shares Fluorouracil (5-FU), Cytotoxic chemotherapy and the tag chembl-universe.
- TreatmentPixantrone
Shares Doxorubicin, Cytotoxic chemotherapy and the tag chembl-universe.
- TreatmentDoxifluridine
Shares Fluorouracil (5-FU), Cytotoxic chemotherapy and the tag chembl-universe.
- TreatmentEthiodized oil
Shares Doxorubicin and the tag chembl-universe.
- TreatmentAltretamine
Shares Cytotoxic chemotherapy and the tag chembl-universe.
- TreatmentOlaratumab
Shares Doxorubicin and the tag chembl-universe.
- TreatmentAlitretinoin
Shares Cytotoxic chemotherapy and the tag chembl-universe.